Stroke is the most common clinical cerebrovascular disease with high disability and mortality rates. The treatment of stroke has been a major problem in neurosurgery for many years. In recent years, with the development of endovascular interventional technology, endovascular embolization has become more and more widely used, and has become a very important part of the comprehensive treatment of cerebrovascular diseases. This time, the LAVA liquid embolization system brought by NeuroSafe Medical Co., Ltd. will further improve the effect of embolization treatment of cerebrovascular diseases, and it is expected to further expand its application in the treatment of cerebrovascular diseases, so that more patients who suffer from pain and life-threatening patients with cerebral arteriovenous malformations benefit from it.
LAVA liquid embolic system is mainly composed of organic compounds and polymers. The LAVA liquid embolization system successfully passed the CE certification and obtained the certificate in May 2021, becoming the "first certificate" for neurointerventional products of the same type to go overseas. The clinical use of the product has won unanimous praise from overseas doctors. At present, the LAVA liquid embolization system is expected to complete clinical trials in 2023 and obtain NMPA registration in 2024.
Compared with the same type of products in the existing market, the LAVA liquid embolization system manfactured by NeuroSafe has the following characteristics:
1. Non-adhesive material: the injection resistance is small, and the extubation is relatively easier and safer;
2. Unique low-viscosity formula and the most complete models: LAVA-12, LAVA-18, LAVA34;
3. Better diffusibility and permeability: It deeply penetrate into the lesion and reaches the distal end of tiny blood vessels;
4. Better visibility: the tantalum powder is finer, the sedimentation is slower, and the visibility is clearer.
In order to allow everyone have a more comprehensive understanding, on April 17, 2023 from 19:30 to 20:30, NeuroSafe’s LAVA liquid embolization system will be introduced live in Arterial Yanxuan New Tasting-An arterial online live program. In this event, Mr. Qiu Haiping, the founder of NeuroSafe Medical Co., Ltd., was invited to give you a company introduction, and the Professor Li Youxiang, chief physician of neurosurgery at Beijing Tiantan Hospital, will make a product introduction.